Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

VerSiLiB · Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy

HORIZONStatus: SIGNED1 April 202231 March 2026EU funding €2,994,245Call HORIZON-EIC-2021-PATHFINDEROPEN-01

Robust detection of single molecules in complex biological fluids is the ultimate goal in the field of disease biomarker analysis. Conventionally, to enable the quantitative analysis of individual molecules in macroscopic volumes, analyte pre-concentration and sample partitioning into fL-nL compartments has been combined with the amplification of the specific recognition events. In these setups, the positive or negative detection of fluorescence signal is triggered by enzymatic reactions occurring in each compartment. Binary readout based on Poisson statistics quantifies ultra-low concentrations of analyte molecules. This approach has been adopted for nucleic acids analysis in current digital PCR, and is also available for proteins in a technique coined as digital ELISA.The objective of VerSiLiB is to develop an enzyme-free amplification strategy for the analysis of both protein and nucleic acid analytes with the single digital platform that offers means to access additional information on target analytes not achievable with current technologies. Method is based on novel affinity-mediated-transport amplification, where affinity interaction of target analyte with a specific ligand attached to a magnetic nanoparticle transporter is accompanied with rapid shuttling of fluorescent tracers that serve as reporters. By applying external magnetic field, tracers are transported from the tracer storage side (where they are dark) to tracer active side (where they become bright) only if target analyte is present in the small reaction compartment. Tailored plasmonic nanostructures will be prepared at the storage and active sides of the compartment to render the tracer either dark or bright. The aim is to perform technology validation for the novel VerSiLiB proteogenomics amplification platform in cancer management using biobanked liquid biopsy samples.

Consortium · 8 organisations

coordinator

TEKNOLOGIAN TUTKIMUSKESKUS VTT OY

FI · €878,464

participant

AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH

AT · €77,032

participant

UNIVERSITA DEGLI STUDI DI CATANIA

IT · €495,410

participant

PROCOMCURE BIOTECH GMBH

AT · €449,499

participant

Proteins.1 Oy

FI · €25,147

participant

FYZIKALNI USTAV AV CR, VVI

CZ · €422,002

participant

FINNADVANCE OY

FI · €196,692

participant

ISTITUTI FISIOTERAPICI OSPITALIERI

IT · €450,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.